Business Standard

Sunday, February 16, 2025 | 05:22 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Viewing the Indian pharma sector through the biosimilar lens

Budget is expected to provide certain incentives to promote innovation & in-house R&D in the sector

Prof V K Unni of IIM Calcutta
Premium

Prof V K Unni of IIM Calcutta

Prof V K Unni
The Indian pharmaceutical market which would rank amongst the top five in terms of volume is also the largest provider of generic drugs globally. This has earned India the sobriquet “pharmacy of the developing world”. It is estimated that Indian pharmaceutical companies supply around 80 per cent of the antiretroviral drugs that are being used on a global scale to deal with AIDS. 

The sector, which is valued at around $ 35 billion, is expected to cross $ 50 billion by 2019-20. This sector also attracts considerable Foreign Direct Investment (FDI) with inflows crossing $ 13 billion during the last

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in